Extreme Hypofractionation with SBRT in Localized Prostate Cancer.
Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological...
| Publicado en: | Current Oncology Vol. 28; no. 4; pp. 2933 - 2950 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Aug2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152137446&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 152137446 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Aug2021 vid: 28 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 152137446 10.3390/curroncol28040257 152137446 ppf: 2933 ppct: 17 formats: fmt: @attributes: type: P tig: atl: Extreme Hypofractionation with SBRT in Localized Prostate Cancer. aug: au: Antonia Gómez-Aparicio, Maria Valero, Jeannette Caballero, Begoña García, Rafael Hernando-Requejo, Ovidio Montero, Ángel Gómez-Iturriaga, Alfonso Zilli, Thomas Ost, Piet López-Campos, Fernando Couñago, Felipe affil: Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain sug: ab: Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological insights to shorten the overall treatment time, improving the control of the disease without increasing toxicities. Stereotactic body radiation therapy (SBRT) represents an extreme form of hypofractionated radiotherapy in which treatment is usually delivered in 1-5 fractions. This review assesses the main efficacy and toxicity data of SBRT in non-metastatic prostate cancer and discusses the potential to implement this scheme in routine clinical practice. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|